GT Biopharma Inc.

GTBP | NASDAQ

Price Alert Chart Builder DCF Calculator

$7.18

$0 (0.00%)

At close: Sep 22, 2026, 4:00 PM ET

$7.20

+$0.02 (+0.25%)

After-hours: Sep 22, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $9.06M

Enterprise Value $4.1M

Beta 0.91

Average Volume 1.56M

Shares Outstanding (Diluted) 1.55M

Shares Change YoY 1300.57%

Institutional Ownership 13.50%

Exchange NASDAQ

ISIN US36254L3087

Price Performance

Price Change 1M -0.8%

Price Change 3M -41.9%

Price Change 6M -38.3%

Price Change YTD -64.9%

Price Change 1Y -64.1%

Price Change 3Y -96.1%

Price Change 5Y -99.9%

1M CAGR (ann.) -10.3%

1Y CAGR (ann.) -64.8%

5Y CAGR (ann.) -74.1%

All-Time CAGR -70.9%

Valuation

PE Ratio -0.07

Forward PE N/A

PEG Ratio 0.00

Forward PEG 0.00

PS Ratio N/A

Forward PS 0.10

PB Ratio 2.54

P/FCF Ratio -0.63

P/Adj. FCF Ratio -0.59

P/OCF Ratio -0.77

EV/Sales N/A

EV/EBIT -0.20

EV/EBITDA -0.20

EV/FCF -0.28

Earnings Yield -1448.5%

FCF Yield -159.2%

Adj. FCF Yield -169.2%

Financial Health

Net Cash $4.96M

Total Debt $0

Cash & Short-Term Investments $4.96M

Total Assets $5.79M

Current Ratio 2.61

Quick Ratio 2.61

Debt / Equity Ratio 0.00

Debt / EBITDA -0.00

Debt / FCF -0.00

OCF / Debt N/A

Interest Coverage -128.64

Altman Z-Score -185.32

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -6.3%

Returns

Return on Assets -381.5%

Return on Equity -443.1%

Return on Invested Capital -457.8%

Return on Capital Employed -457.8%

Return on Tangible Assets -381.5%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y 32.9%

EPS CAGR 5Y 32.1%

EPS CAGR 10Y 51.0%

FCF CAGR 3Y -11.1%

FCF CAGR 5Y 3.1%

FCF CAGR 10Y -9.9%

Analyst Forecasts

Analyst Rating Hold

Analyst Count 0

EPS Growth Next 3Y 33.4%

Revenue Growth Next 3Y N/A

Earnings Date Nov 12, 2026

EPS Estimate (next Q) -$2.50

EPS Growth Est (next Q) 201.2%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Cash Flow

Operating Cash Flow $-14.43M

Free Cash Flow $-14.43M

Adj. Free Cash Flow $-15.33M

FCF Per Share -$9.29

OCF Per Share -$9.29

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $0

Operating Income $-16.34M

EBITDA $-20.33M

Net Income $-22.08M

EPS (Diluted) -$104

Revenue / Employee N/A

Profit / Employee $-22.08M

Employees 1